^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NRAS mutation

    i
    Other names: NRAS1, HRAS1, N-Ras Protein Part 4, Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, NRAS, Neuroblastoma RAS Viral Oncogene Homolog, NRAS Proto-Oncogene, GTPase
    Entrez ID:
    4893
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    Apply
    Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer (NCT02152995)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    08/14/2014
    Primary completion :
    08/25/2021
    Completion :
    01/25/2026
    HER-2 • KRAS • BRAF • NRAS • HRAS • EGF
    |
    KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61
    |
    Mekinist (trametinib) • omipalisib (GSK2126458)
    Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial (NCT05554328)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    04/25/2023
    Primary completion :
    10/01/2028
    Completion :
    10/01/2028
    KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2
    |
    KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation
    |
    Lynparza (olaparib) • Koselugo (selumetinib)
    A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors (IMM1104-101) (NCT05585320)
    Phase 1/2
    Immuneering Corporation
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    10/31/2022
    Primary completion :
    06/01/2026
    Completion :
    06/01/2027
    KRAS • HRAS • APC
    |
    KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • atebimetinib (IMM-1-104)
    Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS (NCT04708054)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    10/21/2021
    Primary completion :
    12/31/2027
    Completion :
    12/31/2027
    KRAS • NRAS • DNMT3A • NF1 • RUNX1 • ASXL1 • PTPN1
    |
    TP53 mutation • KRAS mutation • NRAS mutation • RAS mutation
    |
    Venclexta (venetoclax) • cladribine • fludarabine IV • thiotepa • busulfan
    PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (PARERE) (NCT04787341)
    Phase 2
    Gruppo Oncologico del Nord-Ovest
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    12/15/2020
    Primary completion :
    06/15/2025
    Completion :
    12/15/2025
    KRAS • BRAF • NRAS
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
    |
    Avastin (bevacizumab) • Vectibix (panitumumab) • Stivarga (regorafenib) • oxaliplatin • irinotecan
    A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3) (NCT05039177)
    Phase 1/2
    Erasca, Inc.
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    09/20/2021
    Primary completion :
    08/01/2025
    Completion :
    12/01/2025
    KRAS • BRAF • NRAS
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
    |
    Erbitux (cetuximab) • Ibrance (palbociclib) • Braftovi (encorafenib) • ERAS-007
    Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors (NCT02079740)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    03/26/2014
    Primary completion :
    12/01/2022
    Completion :
    03/07/2025
    KRAS • NRAS • BCL2L2
    |
    KRAS mutation • NRAS mutation
    |
    Mekinist (trametinib) • navitoclax (ABT 263) • omipalisib (GSK2126458)
    Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab (NCT01814501)
    Phase 2
    John Hays
    Completed
    Last update posted :
    02/05/2025
    Initiation :
    02/01/2013
    Primary completion :
    08/06/2018
    Completion :
    08/06/2018
    KRAS
    |
    KRAS mutation • NRAS mutation • RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium
    A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (Neo ReNi II) (NCT05418972)
    Phase 2
    Melanoma Institute Australia
    Recruiting
    Last update posted :
    01/07/2025
    Initiation :
    08/14/2023
    Primary completion :
    12/01/2025
    Completion :
    12/01/2035
    BRAF
    |
    BRAF mutation • NRAS mutation • NRAS wild-type
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw)
    Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors (NCT03905148)
    Phase 1
    BeiGene
    Recruiting
    Last update posted :
    10/26/2024
    Initiation :
    05/01/2019
    Primary completion :
    09/30/2025
    Completion :
    02/28/2026
    NRAS
    |
    NRAS mutation
    |
    Gomekli (mirdametinib) • lifirafenib (BGB-283)
    Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer (ARMANI) (NCT04678583)
    Phase N/A
    Technische Universität Dresden
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    01/01/2021
    Primary completion :
    12/01/2027
    Completion :
    12/01/2027
    KRAS • NRAS • RAS
    |
    KRAS mutation • NRAS mutation • RAS mutation